Alison Cave
Overview
Explore the profile of Alison Cave including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
263
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Guo Y, Raventos B, Catala M, Elhussein L, Lopez-Guell K, Tan E, et al.
Pharmacoepidemiol Drug Saf
. 2024 Oct;
33(10):e70022.
PMID: 39414581
Purpose: To illustrate the interest in using interrupted time series (ITS) methods, this study evaluated the impact of the UK MHRA's March 2019 Risk Minimisation Measures (RMM) on fluoroquinolone usage....
2.
3.
Chinnery P, Bonnet M, Cave A, Hofer M, Lamb A, McConkey G, et al.
Nat Rev Drug Discov
. 2021 Dec;
21(2):81-82.
PMID: 34876668
No abstract available.
4.
Gini R, Sturkenboom M, Sultana J, Cave A, Landi A, Pacurariu A, et al.
Clin Pharmacol Ther
. 2020 Apr;
108(2):228-235.
PMID: 32243569
Although postmarketing studies conducted in population-based databases often contain information on patients in the order of millions, they can still be underpowered if outcomes or exposure of interest is rare,...
5.
Moseley J, Vamvakas S, Berntgen M, Cave A, Kurz X, Arlett P, et al.
Br J Clin Pharmacol
. 2020 Mar;
86(6):1034-1051.
PMID: 32162368
The understanding of the benefit risk profile, and relative effectiveness of a new medicinal product, are initially established in a circumscribed patient population through clinical trials. There may be uncertainties...
6.
Candore G, Hedenmalm K, Slattery J, Cave A, Kurz X, Arlett P
Clin Pharmacol Ther
. 2020 Jan;
107(4):915-925.
PMID: 31956997
Exploring and combining results from more than one real-world data (RWD) source might be necessary in order to explore variability and demonstrate generalizability of the results or for regulatory requirements....
7.
Cave A, Brun N, Sweeney F, Rasi G, Senderovitz T
Clin Pharmacol Ther
. 2019 Dec;
107(4):753-761.
PMID: 31846513
The increasing volume and complexity of data now being captured across multiple settings and devices offers the opportunity to deliver a better characterization of diseases, treatments, and the performance of...
8.
Cave A, Kurz X, Arlett P
Clin Pharmacol Ther
. 2019 Apr;
106(1):36-39.
PMID: 30970161
No abstract available.
9.
Pacurariu A, Plueschke K, McGettigan P, Morales D, Slattery J, Vogl D, et al.
BMJ Open
. 2018 Sep;
8(9):e023090.
PMID: 30185579
Objective: Electronic healthcare databases (EHDs) are useful tools for drug development and safety evaluation but their heterogeneity of structure, validity and access across Europe complicates the conduct of multidatabase studies....
10.
Plueschke K, McGettigan P, Pacurariu A, Kurz X, Cave A
BMJ Open
. 2018 Jun;
8(6):e021864.
PMID: 29903798
Introduction: A review of European Union (EU)-funded initiatives linked to 'Real World Evidence' (RWE) was performed to determine whether their outputs could be used for the generation of real-world data...